Today: August 17, 2018, 10:51 am

“Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem Cells

“Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem Cells 2017-10-13 23:59:56
Biotech Holdings Announces Effective Induction of “Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem Cells

Microbiome Based Regenerative Company Expands Intellectual Property Portfolio into Autoimmunity Space

Biotech Holdings announced today filing of a patent application entitled “Reverse Abscopal Effect for Treatment of Autoimmunity.” The patent covers recent data showing that injection of ProCell stem cells in one joint of animals suffering from rheumatoid arthritis leads to remission of the disease in all the joints.

The term “abscopal effect” is derived from the area of oncology, in which localized irradiation of cancers in one part of the body, results in tumors regressing at anatomically distant locations, likely as a result of immune system activation.

Scientific collaborators of Biotech Holdings found that administration of Procell leads to generation of T regulatory cells, which enter circulation and suppress autoimmune attack on the other joints.

“In autoimmune diseases, conditions where the body’s immune system attacks healthy cells of the body, the T regulatory cell plays a fundamental role in specifically stopping the ongoing pathological immune response. Said Thomas Ichim, Ph.D, President and CEO of Biotech Holdings. “Unfortunately, the specific molecules of the body that the immune system is attacking in autoimmunity are different from patient to patient and are not fully known. Accordingly, the finding that Procell can cause remission of autoimmunity, without the need to know patient-specific molecules, places this approach in an ideal position.”

According to the NIH, 50 million of Americans suffer from autoimmune diseases, which are one of the top 10 cause of death in women under the age 65. It is estimated that 75% of autoimmune patients are female.

About Biotech Holdings

Biotech Holdings was founded on technologies and patents developed by Dr. Amit Patel and Dr. Thomas Ichim focused on identifying interactions between gut bacteria (microbiome) and stem cells. The Company has identified several bacterially derived compounds that enhance stem cell activity and is applying these to chronic diseases associated with circulation deficiencies. Initial therapeutic indications the company is targeting are: Critical Limb Ischemia and Ischemic Heart Failure. The Company has 10 patent applications filed covering stem cell modulation, augmentation, and differentiation by bacterial compounds.


Thomas E Ichim, Ph.D

President and Chief Executive Officer

BioTech Holdings

9255 Towne Centre Drive, #450

San Diego, CA 92121

858 353 4303

Twitter: @biotechholdings

Press Information
Biotech Holdings
9255 Towne Centre Drive #450

San Diego

California 92121

Thomas Ichim
858 353 4303

# 381 Words
Related Articles
More From Health
Drug Abuse Treatment Market to Surpass US$ [..]
(EMAILWIRE.COM, August 06, 2018 ) Global Drug Abuse Treatment Market, by Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, [..]
Sponsors Recommend Novotech for CRO Leadership Award
SYDNEY, Aug 9, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech has been awarded the "Exceeded Customer Expectations" [..]
Nurse Staffing Agency Website Focuses on Services; [..]
Elkhart, IN; August 1, 2018 – Excellent Nursing Services, Inc. (ENS) has announced the launch of the agency’s website highlighting [..]
Ascletis-developed Ganovo Acquired Extraordinary Achievement
Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association HONG [..]
Primary Sclerosing Cholangitis Market to Reach US$ [..]
(EMAILWIRE.COM, July 30, 2018 ) Global Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.